secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0001193125-23-064580
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam expands board to 13, elects Peter N. Kellogg as Class II director
-------------------------------------------------------------------------

- Board expanded from 12 to 13 directors; Kellogg fills new vacancy effective March 7, 2023.
- Kellogg will serve as Class II director until 2024 annual meeting and is expected to join the Audit Committee.
- Non-employee director cash fee $55,000 (rising to $60,000 April 1, 2023); stock option for 4,948 shares at $194.34 strike.
- Option vests ratably over three years; annual equity awards begin 2024 with $400,000 grant-date value.
- Indemnification agreement entered with the Company consistent with other non-employee directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000119312523064580/0001193125-23-064580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000119312523064580/d481911d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-064580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer